H-P Hartung

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

CH Polman, Ludwig Kappos, Mark S. Freedman et al. · Journal of Neurology · 2007 · 75 citations · Full text

Autoimmune Disease, Medicine, Immunology +8

Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker

D. Krametter, G. Niederwieser, Andrea Berghold et al. · Multiple Sclerosis Journal · 2001 · 38 citations

Definite Multiple Sclerosis, Disease Activity Marker, Autoimmune Disease +15

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis

H-P Hartung, Thomas Berger, R. Bermel et al. · Multiple Sclerosis and Related Disorders · 2020 · 26 citations · Full text

Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study

Giacomo P. Comi, Frederik Barkhof, Luca Durelli et al. · Multiple Sclerosis Journal · 1995 · 16 citations

Ocular Disease, Immunology, Neurological Progress +18

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

MS Freedman, Carola Metzig, Ludwig Kappos et al. · Multiple Sclerosis Journal · 2011 · 13 citations · Full text